Category: MEMBER NEWS

ProNAi Therapeutics, Inc., a private DNAi cancer drug development company, recently concluded its initial human clinical trial of PNT2258. The company also expanded its management team with the recent appointments of board member and venture capital investor Mina Sooch, MBA, as President and CEO, and Dr. Richard Messmann, MD, as Chief Medical Officer.

Two MVCA members, Augment Ventures and MK Capital recently made investments in LLamasoft, Inc., the global leader in supply chain design software. LLamasoft enables companies to model, optimize and simulate their supply chain network, leading to major improvements in cost, service, sustainability, and risk mitigation, with unparalleled supply chain design and predictive analytics solutions. “LLamasoft […]

Renaissance Venture Capital Fund recently made its first investment commitment from its Renaissance II fund. The commitment was made to Allos II, a Cincinnati and Indianapolis-based venture capital fund targeting investments in early-stage technology companies based in the Midwest.  The fund’s investor group, which includes institutional investors such as Indiana University Foundation, Purdue University and […]

MEMBER PRESS RELEASE: Atterocor Launches Innovative Company Focused on Accelerated Development of Treatment for Adrenal Cancer; Secures $16 Million Series A Financing Life Sciences Investors Frazier Healthcare and 5AM Ventures Lead the Round Ann Arbor, Michigan – August 3, 2012 – Atterocor, Inc., a company developing an innovative therapy for adrenal cancer, today announced a […]